Executive advancement is not easy for anyone, but you only have to look at the photographs of the board of directors in a few annual reports to see that it is much harder for women.Many factors beyond our control have kept most of us out of the upper echelons of management, but there are a few factors that hurt us nearly as much – and those, we can choose to do something about.
For the younger women I meet now, gender is less of an issue than managing particular personality types. Where they tend to struggle is not with peers but their supervisors, more male-heavy executive teams where there is not yet a lot of diversity. I also see women being their own worst enemies sometimes by being overly competitive with each other when the real challenge is creating more opportunities for all of us.
HCL’s EXACTO Intelligent Automation Streamlines Bank Trade Processing
At this time, the trend toward as-a-service consumption continues to grow. In a world where mixtures of on-prem as well as public and private cloud systems and applications make up the IT infrastructure, traditional operating models are unable to deliver the proper balance of agility, control, and scalability.
Today’s most successful adherence programs are no longer one-way communications solely about the product. Rather, they employ a more holistic approach that encourages patient interaction.
Every patient is unique and every patient’s journey is unique. That’s why it’s important to allow the patient to drive the topics and the cadence of the engagement based on what’s happening in that patient’s journey at that particular time. Patient journeys evolve based on a number of factors such as how recently they’ve been diagnosed, how they’re doing on the therapy and how they’re feeling.
Medical monitoring is an essential component of the clinical research process. Medical monitors provide medical expertise and oversight for the entire clinical trial, from initial study design through final study close-out. They ensure the clinical integrity of the trial subjects and provide safety accountability across the duration of the study, while acting as expert points of reference for both investigative sites and study team members.
Recently I had an interesting question posed to me. Someone asked me to help explain to management at his company what happens when the drug safety (DS)/pharmacovigilance (PV) group does not do a good job! Management wanted to know why they needed to continue to invest in more and more resources to report bad things about the company’s products.
In the course of many years in pharma heading drug safety groups and now consulting, training and doing outreach to the public, I continue to be amazed and humbled by the lack of knowledge by the public about drug safety and what those little pills you pop in your mouth can do.
